Supplement Guide | Biomarkers 03 | What to Do With Your Numbers (And What They Can't Tell You)

To read part 1 in the series, click here.

To read part 2 in the series, click here.

Getting your lab results back should feel like progress. And it is. But a number on a panel doesn't tell you what to do next. It doesn't tell you how to weigh a single data point against your broader health picture. It doesn't tell you what "normal" really means, or whether normal is good enough. It doesn't tell you when to act and when to wait.

That's what this article is for.

The bottleneck isn’t always access to data. It is often the distance between a result and a decision.

A Single Snapshot Isn't a Story

The first thing to understand about many biomarkers is that one reading, taken at one moment in time, is limited information. Fasting glucose fluctuates with sleep quality, stress, and what you ate the day before. Cortisol is time-of-day dependent. hs-CRP can spike with acute inflammation, including a hard workout or a minor infection. A single data point can point you in a useful direction. It can also mislead you if you treat it as a verdict.

The value of biomarker tracking compounds over time. A fasting glucose of 94 mg/dL means something different if your previous reading was 88 than if it was 102. A vitamin D level of 31 ng/mL means something different in October than in March, especially if you live somewhere that gets little sun through the winter. Trends are what tell the story. Single readings are just chapters.

For the markers covered in Part 2, a reasonable retesting window after starting a supplement intervention is two to six months. That's long enough for meaningful change to show up in most markers. Triglycerides and fasting glucose can shift within that window with consistent omega-3 or berberine use. RBC magnesium may take a bit longer to reflect cellular repletion. Vitamin D levels respond steadily but not overnight, particularly if you're starting from a low baseline.

Reference Range vs. Optimal Range

This distinction matters more than many people realize. Reference ranges on lab reports are derived from population distributions. They tell you roughly where the middle of the bell curve sits. They are intended to flag disease, not to define optimal function.

Serum magnesium is a good example. A reading can sit within the reference range while still reflecting cellular stores that are lower than ideal for sleep quality, muscle function, and metabolic health. Vitamin D levels below 30 ng/mL are flagged as low on many panels, but a growing body of research suggests functional benefits may require levels closer to 40 to 60 ng/mL. The reference range tells you where most people are. It doesn't tell you where you want to be.

This is worth raising with your doctor. Many clinicians are open to a conversation about functional optimization when a patient comes in with their own data and specific questions. The framing that works best: "My levels are within range, but I want to understand whether there's a case for targeting a higher level based on the research." That's a different conversation than arriving with a supplement recommendation and asking for sign-off. Bring the data, ask the question, and let the discussion follow from there.

The Testing Anxiety Problem

More data should mean more clarity. In practice, it doesn't always work that way. Expanded panels surface numbers that standard panels don't report, and some of those numbers may come with uncertainty attached. If you've run a comprehensive panel and found a result that unsettled you, that's a real and reasonable response.

A few principles that help:

• First, an abnormal result on a single test is a signal to investigate, not a diagnosis. It means something worth paying attention to, not necessarily something wrong

• Second, many markers that appear alarming in isolation look different when viewed alongside related markers. Elevated hs-CRP paired with recent intense exercise tells a different story than elevated hs-CRP alongside metabolic dysfunction across multiple markers. Context is everything

• Third, expanded testing can reveal insights that standard panels miss, and learning about those things early is the whole point. A low ferritin reading caught before it becomes symptomatic is information that works in your favor

The goal is to become a more fluent reader of your own data over time. That fluency builds with each panel, not from a single reading.

When a Number Moves and Your Health Doesn't (Yet)

This is the part where I want to be direct, because the supplement industry often isn't.

There are two different kinds of biomarker change worth distinguishing. A pharmacodynamic marker tells you that a mechanism is working, that a supplement is doing what it's supposed to do at the biological level. A clinical endpoint tells you that a meaningful health outcome has changed. These are related but not the same thing, and the gap between them is where a lot of supplement overclaiming happens.

Vitamin D is the clearest example I can give you. Raising your marker with D3 supplementation is well-established and reproducible. The marker moves reliably. Whether raising that marker translates to reduced fracture risk, better immune function, or other downstream clinical outcomes is a considerably more complicated question. Large RCTs including the VITAL and D-Health trials have not shown reduced fractures for generally vitamin D-replete adults from supplementation alone. Umbrella reviews of systematic reviews and meta-analyses of RCTs have found no evidence that supplementation with vitamin D alone reduces fracture risk in populations that aren't severely deficient. Meanwhile, an older meta-analysis of over 31,000 individuals in 2012 found that daily intake of 800 IU or more reduces hip fractures by 30% and nonvertebral fractures by 14%, with lower doses failing to produce the same effect.

What that means in practice: if you're severely deficient, supplementing D3 almost certainly matters clinically. If you're replete or mildly insufficient, moving the marker may be meaningful or it may not be, and the research hasn't settled that question cleanly for certain outcomes. The marker is movable. What it moves toward is more complicated.

This is not an argument against supplementing vitamin D, or against tracking any of the markers in Part 2. It's an argument for holding the data with appropriate humility. A number improving on your panel is a good sign. But it's just the beginning of the story… not the end of one.

Your data tells you where to aim. It doesn't guarantee what you'll hit. That gap is where good judgment lives.

What to Do Next

If you've run a panel, here's a practical framework for working through it.

• Identify which markers are outside reference range and by how much. Small deviations in isolation are different from multiple markers trending in the same direction. Look for patterns, not just outliers.

• Cross-reference with Part 2. For the eight markers covered there, the evidence base for supplements is reasonably strong. Start with the markers where your results and the evidence align.

• Bring your data to your doctor. Frame it as a collaborative conversation. Clinicians sometimes respond better to questions than to supplement recommendations, and their input on your full clinical picture is genuinely valuable.

• Choose one (maybe two) supplements, not six. Stacking multiple supplements at once makes it impossible to know what's working. Start focused, retest in two to six months, and build from there.

• Retest consistently. The same time of day, the same fasting status, the same lab where possible. Consistency in testing conditions is what makes trend data meaningful.

The goal isn't a perfect panel. It's a panel that's moving in the right direction, over time, for reasons you understand. That's what turning data into decisions actually looks like.